DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 Goldman - 2 — - 1 HENRY - 1 Gen Xers - 1 HENRYs - 1 BI's Noah Sheidlower - 1 DINKS - 1
Top related locs:
COOs North America New York York U.S
Top related orgs:
Service - 1 Business - 1 Consumer Finances - 1 Federal - 1 Tech - 1 Apple - 1 Software - 1 Adobe - 1

Search resuls for: "Rom Holdings"


5 mentions found


☆ Who are the HENRYs? Charts show who makes more than $200,000 and how they earn it
  + stars: | 2024-03-30 | by ( Juliana Kaplan | ) www.businessinsider.com   time to read: +4 min
Unlike many older Americans with a higher net worth, these workers are what's called "HENRYs" — high earners, not rich yet. Most HENRYs are ages 40 to 49, although an impressive 5.3% are ages 20 to 29. Credit card balances keep reaching record highs, and Fortune found that American cardholders have, on average, $5,733 in credit card balances. Like other consumers, HENRYs carry some credit card debt, and just under half have credit card balances. Even so, HENRYs tend to earn their money the same way as most Americans: They work a job that earns wages.
Persons: —, HENRY, Gen Xers, HENRYs, BI's Noah Sheidlower, DINKS, Fortune Organizations: Service, Business, Consumer Finances
☆ Goldman's strategy for higher rates and volatility: Buy these stocks with high cash returns
  + stars: | 2023-10-20 | by ( Brian Evans | ) www.cnbc.com   time to read: +3 min
Goldman Sachs is eyeing stocks that can best navigate a high interest rate environment. Goldman Sachs said stocks with a history of exceptional financial returns can help ride out the volatility. All the stocks that made the cut have a buy rating from Goldman Sachs. Shoe giant Nike stock has slipped more than 11% from the start of the year amid worries about consumer spending and a slowing economy. NKE YTD mountain Nike stock.
Persons: Goldman Sachs, Jerome Powell, Goldman, Michael Ng, Ng, Kash Rangan, Kate McShane Organizations: Federal, Tech, Apple, Software, Adobe, Nike, Investors
☆ Activist Elliott makes inroads at Catalent to build value. Here’s what could happen next
  + stars: | 2023-09-16 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +7 min
This segment also handles the formulation, development and manufacturing for parenteral dose forms, including vials and prefilled syringes. Activist Commentary: Elliott is a very successful and astute activist investor, particularly in the technology sector. While as an activist Elliott will do whatever it feels is necessary to enhance shareholder value, in the past the firm has made significant use of the strategy of offering to acquire its portfolio companies as the best catalyst to enhance shareholder value. Like Catalent, Syneos is an outsourced pharma solutions company: It outsources R&D for pharmaceutical companies, whereas Catalent outsources manufacturing. If this does turn from a strategic review to an operational review, there is no guarantee that he keeps his job.
Persons: Catalent, there's, Elliott, Steven Barg, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Johnson, Barg, Ryan, John Greisch, There's, Danaher, Alessandro Maselli, Ken Squire Organizations: Oral Technologies, Clinical, Pfizer, Rom Holdings, Bloomberg, Merck, Citrix Systems, Nielsen Holdings, Square, Veritas Capital, Syneos Health, 13D Locations: COOs, North America
☆ Goldman Sachs CEO David Solomon warns of pain ahead for commercial real estate
  + stars: | 2023-06-12 | by ( Hugh Son | ) www.cnbc.com   time to read: +2 min
CEO David Solomon, Goldman Sachs, during a Bloomberg Television at the Goldman Sachs Financial Services Conference in New York, Dec. 6, 2022. Goldman Sachs CEO David Solomon said Monday that his bank will disclose markdowns on commercial real estate holdings as the industry grapples with higher interest rates. Solomon told CNBC's Sara Eisen the New York-based firm will post impairments on loans and equity investments tied to commercial real estate in the second quarter. "There's no question that the real estate market, and in particular commercial real estate, has come under pressure," he said in an interview on CNBC's "Squawk on the Street." Goldman posted almost $400 million in first-quarter impairments on real estate loans, according to Solomon.
Persons: David Solomon, Goldman Sachs, Solomon, CNBC's Sara Eisen, Goldman Organizations: Bloomberg Television, Goldman Sachs Financial Services Locations: New York, York, U.S
☆ Exclusive: Thermo Fisher, Celltrion vie for Baxter's biopharma unit -sources
  + stars: | 2023-03-20 | by ( Anirban Sen David Carnevali | Anirban Sen | David Carnevali | ) www.reuters.com   time to read: +2 min
March 20 (Reuters) - U.S. scientific instruments maker Thermo Fisher Scientific Inc (TMO.N) and South Korea's Celltrion Inc (068270.KS) are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (BAX.N), according to people familiar with the matter. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co (KKR.N) and Carlyle Group (CG.O), have also expressed interest in the Baxter business, the sources said. Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.
0 next >>
Total: 5